Loading stock data…
WGS
$56.33+4.53 (+8.75%)
After Hours$56.33+0.00 (+0.00%)· Last close Jun 9
GeneDx Holdings Corp., a genomics company, provides genetic testing services.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
GeneDx Holdings Corp. in the Healthcare sector is trading at $56.33 with a market capitalization of $1.6B. Wall Street consensus targets $77.00 (9 analysts), implying a +36.7% move over the next 12 months. The stock is currently near its 52-week low of $32.21, remaining 44.7% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 77 is overbought against a weak tape. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +36.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 77 against a weak tape — risk of pullback
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$56.33
Potential Downside
0%
Whystock Fair Value$56.33
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus9 analysts
Mean target$77.00+36.7%
Range$50.00 – $100.00
Fundamentals
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also dev...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.57B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.07
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-30.62%
Volume
Today's trading volume
1.38M
Recent News
GeneDx Holdings (WGS) Valuation After Q1 2026 Earnings Miss Guidance Cut And Legal Scrutiny
Q1 shock, guidance cut and legal actions put GeneDx Holdings (WGS) under scrutiny GeneDx Holdings (WGS) has been in focus after a substantial Q1 2026 earnings miss, a much higher net loss, a 12% cut to full year revenue guidance and a large Fabric Genomics impairment. These financial updates, combined with multiple securities law firms launching investigations and class action lawsuits over alleged misstatements, have contributed to sharp recent volatility in GeneDx Holdings stock. See our...
From Industry Titans to Tiny Fish: 3 Key Stocks Insiders are Trading
Check out these three stocks that insiders are buying and selling, including giants in oil and AI, as well as a small gene stock seeing huge swings.
This Healthcare Investor Added $43 Million to a Genomics Leader Growing Volume 34%
GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.
Ashland, GeneDX Holdings, and 3 More Stocks See Action From Activist Investors
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.
Is GeneDx Stock a Buys After a Company Director Purchased Over 350,000 Shares?
AI-driven health intelligence provider GeneDx attracted a notable insider buy, as recent filings highlight activity amid a volatile year.